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QUESTIONS
1. What was the rationale for using VEGF to treat diabetic wounds?
2. What studies were carried out to demonstrate that VEGF improved diabetic wound healing?
3. What methods were used to study the mechanisms by which VEGF improved wound healing?
4. What are the limitations of this study?
5.  What obstacles may prevent the application of findings from animal wound healing studies  
to the treatment of human chronic wounds?
Nonhealing wounds are a major complication of diabetes. Diabetic foot ulcer-
ations (DFUs) affect 12–15% of patients with diabetes mellitus during their lifetime 
(Reiber et al., 1995). As a result, DFUs impair quality of life, cause significant mor-
bidity, and account for 20% of all diabetes-related hospital admissions. A majority 
of neuropathic DFUs fail to heal even after 5 months of therapy, and foot ulcers 
precede 85% of nontraumatic amputations in patients with diabetes, indicating a 
need for better therapy (Margolis et al., 1999).
One growth factor—topically applied recombinant platelet-derived growth factor—is currently approved by the 
US Food and Drug Administration for the treatment of neuropathic DFUs (Boulton et al., 2004). Its clinical success 
is limited in part by the need for daily application and the hostile proteolytic wound environment in which the 
protein is applied. Sustained growth factor delivery would have advantages, and vascular endothelial growth fac-
tor (VEGF), a potent angiogenesis-stimulating growth factor, is thought to have therapeutic potential for diabetic 
vascular disease and ulcers.
In a study reported in this issue, Brem and colleagues (2009) sought to determine whether one isoform of VEGF, 
VEGF165, delivered to wounds by an adenovirus vector (ADV), would improve healing. After the investigators had 
established the ability of the ADV/VEGF165 to produce VEGF effectively, they used it to treat wounds in nonobese 
diabetic and db/db mice. ADV/VEGF165-treated wounds exhibited accelerated wound healing. The authors then 
studied the mechanisms by which ADV/VEGF165 works. They found that ADV/VEGF165 enhanced tensile stiffness, 
epithelialization, and collagen deposition.
Through the following questions, we examine this paper in greater detail. For brief answers, please refer to 
the supplementary material online.
references
Boulton AJ, Kirsner RS, Vileikyte L (2004) Clinical practice. Neuropathic diabetic foot ulcers. N Engl J Med 351:48–55
brem H, Kodra a, Golinko MS, Entero H, Stojadinovic o, Wang VM et al. (2009) Mechanism of sustained release of vascular endothelial growth factor 
in accelerating experimental diabetic healing. J Invest Dermatol 129:2275–87
Margolis DJ, Kantor J, Berlin JA (1999) Healing of diabetic neuropathic foot ulcers receiving standard treatment. A meta-analysis. Diabetes Care 22:692–5
Reiber GE, Boyko EJ, Smith DG (1995) Lower extremity foot ulcers and amputations in diabetes. In: Diabetes in America (Harris MI, Cowie CC, Stern MP, 
Boydo EJ, Reiber GE, Bennett PH, Eds.), 2nd edn. DHHS pub. no. (NIH) 95-1468. US Government Printing Office: Washington, DC.
Vascular endothelial Growth factor Delivery  
via Gene Therapy for Diabetic Wounds: first steps
Tace Rico1, Jeremy Green1 and Robert S. Kirsner1
Journal of Investigative Dermatology (2009) 129, 2084. doi:10.1038/jid.2009.235
1Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, Florida, USA
VEGF-stimulated wound healing at day 16.
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Nonhealing wounds are a major complication of diabetes. Diabetic foot ulcerations (DFUs) affect 12–
15% of patients with diabetes mellitus during their lifetime (Reiber et al., 1995). As a result, DFUs 
impair quality of life, cause significant morbidity, and account for 20% of all diabetes-related hospital 
admissions. A majority of neuropathic DFUs fail to heal even after 5 months of therapy, and foot 
ulcers precede 85% of nontraumatic amputations in patients with diabetes, indicating a need for better 
therapy (Margolis et al., 1999).  
 One growth factor—topically applied recombinant platelet-derived growth factor—is currently 
approved by the US Food and Drug Administration for the treatment of neuropathic DFUs (Boulton et 
al., 2004). Its clinical success is limited in part by the need for daily application and the hostile 
proteolytic wound environment in which the protein is applied. Sustained growth factor delivery 
would have advantages, and vascular endothelial growth factor (VEGF), a potent angiogenesis-
stimulating growth factor, is thought to have therapeutic potential for diabetic vascular disease and 
ulcers. 
 In a study reported in this issue, Brem and colleagues (2009) sought to determine whether one 
isoform of VEGF, VEGF165, delivered to wounds by an adenovirus vector (ADV) would improve 
healing. After the investigators had established the ability of the ADV/VEGF165 to produce VEGF 
effectively, they used it to treat wounds in nonobese diabetic and db/db mice. ADV/VEGF165-treated 
wounds exhibited accelerated wound healing. The authors then studied the mechanisms by which 
ADV/VEGF165 works. They found that ADV/VEGF165 enhanced tensile stiffness, epithelialization, 
and collagen deposition. 
 Through the following questions, we examine this paper in greater detail. 
 
1. What was the rationale for using VEGF to treat diabetic wounds? 
Diabetic foot ulcers (DFUs) are one of the most common complications of diabetes and a leading 
cause of hospitalization for diabetic patients. For a patient living with diabetes, the lifetime risk of 
developing a DFU is estimated to be 25% (Boulton et al. 2008; Setacci et al., 2009). Setacci et al. 
estimated the annual incidence of DFUs to be 1–4%, and Young et al. (1993) noted in their 
multicenter study of 6,487 diabetic patients that in patients with type 2 diabetes over the age of 60, 
more than 50% had peripheral neuropathy, a condition associated with the majority of DFUs. Owing 
to the prevalence of DFUs, significant health-care resources are spent on the management of ulcers, 
  
including emergency room visits, antibacterial medications, amputations, and a multitude of other 
therapies directed at nonhealing wounds. 
Diabetic patients are found to have many risk factors affecting wound healing, from the 
microenvironment to the macroenvironment. Patients with diabetes often suffer from micro- and 
macrovascular disease. Nerve ischemia due to thickened endoneural blood vessel walls is implicated 
as a cause of neuropathy in these individuals (Ceriello et al. 1999). Patients with peripheral 
neuropathies are at greater risk for ulcer formation because of decreased sensation, but other effects of 
neuropathy may contribute to ulcer development. Foot deformities, such as Charcot foot and 
hammertoes, have also been implicated in impaired wound healing (Falanga, 2005). Many factors 
place the diabetic patient at increased risk for developing an ulcer, but these patients also experience 
difficulty with wound healing. Microvascular disease not only affects nerves but also produces 
thickened basement membrane and arteriolar hyalinosis—conditions that undermine effective wound 
healing by negatively impacting physiological exchanges and leading to decreased migration of 
leukocytes and increased risk for infection (Falanga, 2005). Phenotypic alterations in wound cells in 
patients with diabetes may contribute to inhibited wound healing. Normal epithelialization of acute 
wounds undergoes a progression of stages, including migration, proliferation, and differentiation 
(Usui et al., 2008); the cells of diabetic wounds are described as being fixed in the proliferative stage 
(Falanga, 2004). 
Angiogenesis is necessary for granulation tissue formation as well as for providing oxygen 
and nutrition to wounds (Li et al., 2003). Inadequate angiogenesis in diabetic patients inhibits wound 
healing. By examining the role of vascular endothelial growth factor (VEGF), which promotes 
angiogenesis, the authors sought to promote wound healing in patients with diabetes. 
 VEGF is one of the most potent growth factors in stimulating angiogenesis. It triggers 
endothelial cell division, chemotaxis, and vascular permeability (Ferrara, 1999; Yamagishi et al., 
1999; Griffoen and Molema, 2000; Brkovic and Sirois, 2007; Gavard and Gutkind, 2006) VEGF acts 
in a paracrine manner on dermal microvessels and endothelial cells. It also promotes the production of 
nitric oxide, which enhances collagen deposition. 
VEGF’s main limitation is its short duration of action. In previous experiments using VEGF to 
promote wound healing, frequent applications were required to maintain its efficacy; however, 
standard of care requires the application of compression bandages that remain in place for a week, 
making daily application of VEGF impractical for these patients. Researchers have dealt with this 
problem by using gene therapy to extend VEGF’s duration of action; a vector holds and delivers 
VEGF to ensure continued administration for a period of 1–2 weeks. 
Previous studies with VEGF demonstrated its efficacy in ischemic heart disease. In a gene 
therapy study by Rosengart et al. (1999), two groups of patients received AdVEGF121. The first 
group received injection during a coronary artery bypass graft procedure (CABG) to areas that could 
not be bypassed, and the second group, in whom CABG could not be performed, received VEGF 
injection as their sole therapy. The first group could not be evaluated accurately, as two interventions 
were made. The researchers did note a trend toward decreased ischemia compared with baseline in the 
second group, which received VEGF therapy only. The main contribution of this study, however, was 
delineating the safety profile of the therapy rather than determining its efficacy. 
In 2000, Laitinen et al., in a randomized double-blinded control study, examined catheter-
mediated VEGF plasmid versus percutaneous translumenal coronary angioplasty (PTCA). Patients 
received VEGF after angioplasty but prior to stent implantation. Control subjects received β-
galactosidase or Ringer’s lactate. The investigators concluded that catheter-mediated gene transfer 
therapy was safe and well tolerated for coronary heart disease. At the 6-month evaluation with 
  
angiography, no clinical effects were noted; however, the microvascular angiogenesis expected from 
this therapy may not have been noted by angiography (Laitinen et al., 2000). 
Hedman et al. (2003) examined patients receiving VEGF via a catheter during PTCA. In this 
study, participants were administered VEGF plasmid liposome, a VEGF adenovirus, while controls 
received only Ringer’s lactate. At the 6-month follow-up, patients who had received the VEGF-
adenovirus showed a significant improvement in myocardial perfusion. 
More recently, a replication-deficient adenoviral vector carrying VEGF121 (AdVEGF121) 
was administered to patients via thoracotomy; these patients were compared with others receiving 
maximal medical treatment for severe angina pectoris (Stewart et al., 2006). Patients receiving 
AdVEGF121 therapy demonstrated a significant improvement in exercise capacity and symptoms. 
The researchers also presented data from the autopsy of a participant who died from cardiogenic 
shock following perioperative myocardial infarct as evidence of the benefits of therapy: robust 
neovascularization was evident in the areas that had been injected with AdVEGF121, whereas no new 
vascularization was observed in other areas (Stewart 2006). 
 
2. What studies were carried out to demonstrate that VEGF improved diabetic wound 
healing? 
As a model for type 2 diabetes with increase in lipids, obesity, and insulin resistance, the researchers 
used the db/db mouse, which is homozygous for a mutation making the mouse leptin resistant. These 
mice become obese by 3–4 weeks of age, with elevated blood sugar at 4–8 weeks of age. Wound 
healing in these mice is noted as being delayed. As a model for type 1 diabetes, the researchers chose 
the nonobese diabetic (NOD) mouse, which has a spontaneous phenotype of insulitis. As in humans 
and mice with type 1 diabetes, there is infiltration of the islets with macrophages; dendritic cells; and 
CD4, CD8, and B cells (Giarratana et al., 2007). These models allowed the authors to study wound 
healing in type 1 and type 2 diabetes. 
• VEGF accelerates time to wound closure. Wounds were created in obese diabetic mice (db/db). 
Wounds in mice treated with VEGF were found to heal 6.6 days sooner than those in controls. 
Some mice in this group that received high concentrations of VEGF had an increased mortality. 
• VEGF promotes re-epithelialization, defined as either wound contraction or decreased area of 
open wound and increased area of normal skin pulled into wound. The NOD mice treated with 
VEGF were found to have increased re-epithelialization compared with controls. 
• VEGF increases tensile stiffness. On day 21, when tensile strength in obese diabetic mice was 
examined, no significant differences were noted in load to failure or in stiffness in the NOD 
mice. 
 
3. What methods were used to study the mechanisms by which VEGF improved wound healing? 
Mechanism of VEGF and epithelialization: after determining that VEGF accelerated the time to 
closure and epithelialization, Brem et al. attempted to establish whether this was attributable to 
expedited keratinocyte migration. A migration assay was performed comparing VEGF-treated 
keratinocytes with nontreated keratinocytes. The VEGF-treated keratinocytes showed increased cell 
migration after 24 hours. To ensure that the results of this study represented migration of the 
keratinocytes and not proliferation, the researchers repeated the experiment, treating the keratinocytes 
with mitomycin-C, which inhibits proliferation. The migration results remained significant in the 
VEGF-treated cells. The investigators characterized the keratinocytes affected by VEGF by repeating 
the scratch migration assays using different levels of calcium (which induces keratinocyte 
differentiation) in the medium. VEGF was found to specifically target only activated keratinocytes 
  
that participate in re-epithelialization (lower calcium environment). Differentiating keratinocytes 
(higher calcium environment) were not affected by VEGF. 
 The investigators sought to determine how VEGF promotes collagen deposition (which in turn 
promotes wound contraction). On histological examination, the investigators noted that VEGF-treated 
wounds had increased granulation tissue with larger and more abundant blood vessels than wounds 
treated with saline or empty virus particles. Sirius red staining viewed with polarized light microscopy 
revealed that VEGF-treated wounds demonstrated greater amounts of and more organized collagen 
compared with controls, which had short, random collagen bunches. Interestingly, a third group 
treated with empty virus particles demonstrated longer collagen that was parallel. It was suggested 
that this could be attributed to a more intense inflammatory response in these wounds, prompted by 
the empty virus particles. 
 Mechanism of VEGF and collagen deposition: in an effort to determine the effects of VEGF on 
fibroblasts, the investigators performed scratch migration assays using primary fibroblasts grown 
from patients’ wounds. VEGF had the greatest effect on fibroblasts from the healing edge, whereas 
fibroblasts from the nonhealing edge were unaffected by VEGF. 
 In summary, a well-established proangiogenic growth factor, VEGF, may stimulate wound 
healing via multiple mechanisms: by promoting epithelialization, inducing granulation tissue 
formation and collagen deposition, and promoting angiogenesis. 
 
4. What are the limitations of this study? 
One of the limitations of this study is the lack of other control groups, such as a nondiabetic control. 
The authors may have had the opportunity to further elucidate VEGF in wound healing by using such 
controls. In addition, the wounds studied were not chronic nonhealing wounds, but wounds created in 
mice by the researchers immediately prior to the experiments. While an accepted model, these 
healing-impaired acute wounds do not accurately represent human DFUs, which are often 
nonhealing—as opposed to slow-healing—ulcers. 
The investigators inadequately address the high mortality in the mice treated with high-dose 
adenovirus vector (ADV)-VEGF (the dose that achieved the best results). The authors attribute the 
high mortality of these mice to intolerance of anesthesia. The high mortality is inconsistent with 
previous studies, which demonstrated a positive safety profile in humans. 
 
5. What obstacles may prevent the application of findings from animal wound healing studies 
to the treatment of human chronic wounds? 
Animal models do not duplicate human conditions exactly. For example, the wounds in these mice 
were on the back instead of the extremities (feet), where most diabetic wounds occur. The mouse 
models of diabetes are not exact replications of diabetes in humans, and the exact mechanism of 
diabetes has not been delineated. In other words, these mouse models may represent alternative 
mechanisms of acquiring diabetes. As stated before, the study examined impaired acute wounds rather 
than chronic wounds. Acute and chronic wounds respond differently to treatment, with differing 
attendant growth factors, cytokines, and inflammatory mediators. Therefore, results from an acute 
wound study may not translate directly to chronic wounds. A noncontracting wound model on the tail 
of the mouse exists, but it is unclear whether this is a better model. In the future, Brem et al. may wish 
to explore the use of VEGF in acute wounds in humans by applying ADV-VEGF to punch biopsy 
sites. Issues related to the increased mortality observed in higher-dose groups should also be 
addressed. A clinical trial is nearing completion that utilizes ADV gene delivery (ADV-PDGF) for 
diabetic neuropathic foot ulcers. Thus, the safety profile of this delivery mechanism may soon be 
established in humans. 
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